CA-4948 is a specific inhibitor of IRAK4 that is now being tested in clinical trials in MDS/AML and lymphomas (ClinicalTrials.gov: NCT04278768; NCT03328078) and in preliminary findings has shown a tolerable safety profile. Here, IRAK4 is linked to acute myeloid leukemia.